ArticleWorld journal of transplantation2026
Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study.
Article in World journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandard immunosuppressive regimens result in low rejection rates in the first year after transplantation. However, long-term survival rates after renal transplantation remain relatively poor and are associated with drug-induced side effects.
aimTo assess the effects of switching from traditional mycophenolate mofetil (MMF) combined with steroids and tacrolimus to a low-dose regimen of everolimus and tacrolimus in post-kidney transplant patients, with the aim of reducing the adverse effects of MMF and high-dose calcineurin inhibitors.
methodsThis was a retrospective, single-center study of patients who received a combination therapy of steroids + tacrolimus (low dose) + everolimus (low dose) after kidney transplantation (KT). Data was obtained from patients who underwent KT between 2007 and 2019. Everolimus was initiated at 0.25 mg twice daily, aiming for pre-dose concentrations of 5-7 ng/mL (combined trough levels of tacrolimus and everolimus). Improvement in graft survival was assessed by measuring serum creatinine, urinary protein, and lipid profiles. Safety studies were conducted to observe drug-induced side effects.
resultsWe included 36 patients from a single center. After switching to everolimus, there was a significant reduction in serum creatinine levels which remained stable over one year. Cholesterol levels also improved and remained stable in most patients. Half of the patients reported improvement in their cholesterol levels and continuous stability. Vomiting (47.1%) and diarrhea (32.4%) were the most common adverse effects of MMF treatment. Other side effects included urinary tract infections (20.6%) and anemia (5.9%).
conclusionCombination therapy with everolimus (low dose) + tacrolimus (low dose) was superior to MMF + tacrolimus in terms of a lower incidence of side effects and stable serum creatinine levels over long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.